A Phase 3, Multi-Center, Open-Label Study to Assess the Diagnostic Performance and Clinical Impact of 18F-DCFPyL PET/CT Imaging Results in Men With Suspected Recurrence of Prostate Cancer
Phase of Trial: Phase III
Latest Information Update: 31 Jan 2019
At a glance
- Drugs 18F DCFPyL (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Diagnostic use
- Acronyms CONDOR
- Sponsors Progenics Pharmaceuticals
- 03 Dec 2018 According to a Progenics Pharmaceuticals media release, first patient has been dosed. Data are expected in early 2020.
- 03 Dec 2018 Status changed from not yet recruiting to recruiting.
- 09 Nov 2018 Status changed from planning to not yet recruiting.